TScan Therapeutics
TScan Therapeutics' revenue rose 266.6% to $10 million in fiscal 2025. Its operating margin was −1,315.4%, up from −4,787.7% a year earlier. Free cash flow was −$140 million. The diluted share count rose 15.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
TScan Therapeutics lost money in fiscal 2025: a net loss of $130 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 161 | 120 | 192 | 290 | — |
| Debt incl. finance leases | — | 29 | 30 | 32 | 32 |
| Net debt (negative means net cash) | — | −91 | −162 | −258 | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.3x | 0.2x | 0.1x | 0.3x |
| Interest coverage | — | −56.7x | −24.9x | −36.9x | −49.0x |
| Current ratio | 7.8x | 7.2x | 6.5x | 8.1x | 8.4x |
| Quick ratio | 7.8x | 7.2x | 6.5x | 8.1x | 8.4x |
Cash flow
Projections
Project TScan Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $145,621 of TScan Therapeutics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 23, 2025 | Lynx1 Capital Management LP10% owner | Bought | 6,232 | $0.90 | $5,609 | Form 4 |
| Dec 22, 2025 | Lynx1 Capital Management LP10% owner | Bought | 75,500 | $0.90 | $67,950 | Form 4 |
| Dec 19, 2025 | Lynx1 Capital Management LP10% owner | Bought | 80,069 | $0.90 | $72,062 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 3 of 8 | 3 of 8 |
| Rule of 40 | −250.9% | −4,157.9% | −1,086.6% |
| Altman Z'' | −0.00 | 0.75 | −5.99 |
| Accruals ratio | −11.8% | −5.2% | 1.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 8 | 3 of 8 | 3 of 8 |
Compare
Put TScan Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| TScan Therapeutics | FY25 | 266.6% | −1,315.4% | −1,353.3% | — | — | 3 | |
| Alpha Cognition | FY25 | — | −221.7% | −202.3% | — | — | — | Compare |
| Janux Therapeutics | FY25 | −5.5% | −1,576.7% | −832.8% | — | — | — | Compare |
| Taysha Gene Therapies | FY25 | 17.3% | −1,130.7% | −960.1% | — | — | 4 | Compare |
| Prothena | FY25 | −92.8% | −2,216.4% | — | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 1 | 10 | 14 | 21 | 3 | 10 |
| Revenue growth | — | 834.6% | 33.5% | 55.5% | −86.6% | 266.6% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 21 | 45 | 60 | 88 | 107 | 114 |
| Operating income | −26 | −49 | −67 | −94 | −135 | −136 |
| Net income | −26 | −49 | −66 | −89 | −128 | −130 |
| Diluted EPS (US$) | −28.52 | −4.17 | −2.75 | −1.36 | −1.14 | −1.00 |
| Diluted shares (millions) | 1 | 12 | 24 | 66 | 112 | 130 |
| Cash flow | ||||||
| Cash from operations | −3 | −49 | −66 | −61 | −111 | −135 |
| Capital expenditure | 4 | 10 | 4 | 3 | 4 | 4 |
| Free cash flow | −7 | −59 | −71 | −64 | −115 | −140 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 2 | 5 | 5 | 10 | 12 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 35 | 161 | 120 | 192 | 290 | — |
| Debt incl. finance leases | — | — | 29 | 30 | 32 | 32 |
| Total assets | 50 | 188 | 199 | 272 | 371 | 229 |
| Total liabilities | 32 | 27 | 100 | 121 | 130 | 106 |
| Shareholders' equity | −42 | 161 | 99 | 151 | 241 | 123 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −2,417.8% | −479.6% | −492.3% | −444.0% | −4,787.7% | −1,315.4% |
| Net margin | −2,408.0% | −479.5% | −489.3% | −423.9% | −4,527.7% | −1,256.8% |
| Free cash flow margin | −669.2% | −578.0% | −522.6% | −306.4% | −4,071.3% | −1,353.3% |
| Rule of 40 (growth + FCF margin) | — | 256.6% | −489.1% | −250.9% | −4,157.9% | −1,086.6% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −82.2% | −50.9% | −71.3% | −65.1% | −71.3% |
| Return on assets | — | −40.9% | −34.2% | −37.9% | −39.6% | −43.3% |
| Net debt to EBITDA | — | — | — | — | — | — |